Long VXRTAdd with a relatively small position according to the potential risk.
Factors as illustrated.
VXRT trade ideas
Buy rating+raised about $90 millionshares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.
In this case, B. Riley FBR appears to be very optimistic about the prospects for Vaxart's oral COVID-19 vaccine candidate. This experimental vaccine was recently selected by the U.S. government's Operation Warp Speed for funding and inclusion in a preclinical study.
Keep in mind, though, that it's way too soon to know if Vaxart will be successful. In April, the company reported encouraging results for its oral COVID-19 vaccine candidate in preclinical testing. However, the vaccine candidate hasn't advanced to clinical testing yet.
Now what
Vaxart hopes to advance its oral COVID-19 vaccine candidate to a phase 1 study in the second half of 2020 , potentially as early as this summer. Until that trial begins, probably the main catalyst for the biotech stock will be the results for preclinical testing of its universal oral flu vaccine candidate . This preclinical testing is being conducted in collaboration with Johnson & Johnson.
www.fool.com
The company also raised about $90 million in gross proceeds through at-the-market-facility.
The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.
finance.yahoo.com
Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
The company sold approximately 11.2 million shares at $7.98 per share, the market price at the time of sale.
The additional funds raised through the ATM facility will support the clinical and preclinical development of Vaxart’s product candidates, to conduct clinical trials, to manufacture its products, and for general corporate and working capital purposes.
finance.yahoo.com
VXRT was a top quarterly gainer, rising +376.19%. Expect UptrendVaxart (VXRT, $8) was one of top quarterly gainers, jumping +376.19% to $8 per share. Tickeron A.I.dvisor analyzed 174 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 155 of them (89.09%) charted an Uptrend while 19 of them (10.91%) trended down. Tickeron A.I.dvisor found 135 similar cases when VXRT's price went up 15% within three months. In 83 out of those 135 cases, VXRT's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for VXRT are 61%.
VXRT in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on June 30, 2020
This price move signals that VXRT may fall back below the higher band and head toward the middle band. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 37 of 42 cases where VXRT's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 88%.
$VXRT - Smoke ane Mirrors$VXRT
Pretty obvi that the people who are making money on this are the boys and girls buying up the shares after market close and then dumping on retail during the day.
I see why it is attractive, But have to remember is is 1 of 70 - 100 companies that is a covid play.
Basically its a lotto ticket at this point and you are buying spec and hype.
If you want to gamble, wait for a selloff again tomorrow and pick up some shares in the lower range.
DO NOT BET THE HOUSE.
Vaxart Inc. VXRT Stock AnalysisPrice Volatility is mainly due to the Fundamental Analysis. Not a lot to say on Technical Analysis
Vaxart Inc. VXRT, +28.43% said Friday its oral COVID-19 vaccine has been selected to take part in a nonhuman primate challenge study funded by the U.S. government’s ‘Operation Warp Speed’ program, that aims to accelerate development of a vaccine. Shares were up more than 28%.
NASDAQ:VXRT
Signs Memorandum of Understanding with AttwillVaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating
establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.
AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.
investors.vaxart.com
